NASDAQ: MNPRMonopar Therapeutics Stock
$0.66+0.01 (+1.54%)
Updated Apr 24, 2024
MNPR Price
$0.66
Fair Value Price
$0.53
Market Cap
$11.47M
52 Week Low
$0.27
52 Week High
$1.75
P/E
-1.08x
P/B
2.05x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$8.40M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.32
Operating Cash Flow
-$8M
Beta
0.45
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
MNPR Overview
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how MNPR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MNPR ($0.66) is overvalued by 25% relative to our estimate of its Fair Value price of $0.53 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
MNPR ($0.66) is not significantly undervalued (25%) relative to our estimate of its Fair Value price of $0.53 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
MNPR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more MNPR due diligence checks available for Premium users.
Be the first to know about important MNPR news, forecast changes, insider trades & much more!
MNPR News
Valuation
MNPR fair value
Fair Value of MNPR stock based on Discounted Cash Flow (DCF)
Price
$0.66
Fair Value
$0.53
Overvalued by
25.57%
MNPR ($0.66) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MNPR ($0.66) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MNPR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MNPR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.08x
Industry
15.69x
Market
41.27x
MNPR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.05x
Industry
5.86x
MNPR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MNPR's financial health
Profit margin
Revenue
$0.0
Net Income
-$1.8M
Profit Margin
0%
MNPR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$7.3M
Liabilities
$1.8M
Debt to equity
0.32
MNPR's short-term assets ($7.33M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MNPR's short-term assets ($7.33M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MNPR's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
MNPR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.5M
Investing
$3.0M
Financing
$334.5k
MNPR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MNPR vs Biotech Stocks
Monopar Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.